The effects of temporally secondary co-morbid mental disorders on the associations of DSM-IV ADHD with adverse outcomes in the US National Comorbidity Survey Replication Adolescent Supplement (NCS-A)
- PMID: 24103255
- PMCID: PMC4124915
- DOI: 10.1017/S0033291713002419
The effects of temporally secondary co-morbid mental disorders on the associations of DSM-IV ADHD with adverse outcomes in the US National Comorbidity Survey Replication Adolescent Supplement (NCS-A)
Abstract
Background: Although DSM-IV attention deficit hyperactivity disorder (ADHD) is known to be associated with numerous adverse outcomes, uncertainties exist about how much these associations are mediated temporally by secondary co-morbid disorders.
Method: The US National Comorbidity Survey Replication Adolescent Supplement (NCS-A), a national survey of adolescents aged 13-17 years (n = 6483 adolescent-parent pairs), assessed DSM-IV disorders with the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Statistical decomposition was used to compare direct effects of ADHD with indirect effects of ADHD through temporally secondary mental disorders (anxiety, mood, disruptive behavior, substance disorders) in predicting poor educational performance (suspension, repeating a grade, below-average grades), suicidality (ideation, plans, attempts) and parent perceptions of adolescent functioning (physical and mental health, interference with role functioning and distress due to emotional problems).
Results: ADHD had significant gross associations with all outcomes. Direct effects of ADHD explained most (51.9-67.6%) of these associations with repeating a grade in school, perceived physical and mental health (only girls), interference with role functioning and distress, and significant components (34.5-44.6%) of the associations with school suspension and perceived mental health (only boys). Indirect effects of ADHD on educational outcomes were predominantly through disruptive behavior disorders (26.9-52.5%) whereas indirect effects on suicidality were predominantly through mood disorders (42.8-59.1%). Indirect effects on most other outcomes were through both mood (19.8-31.2%) and disruptive behavior (20.1-24.5%) disorders, with anxiety and substance disorders less consistently important. Most associations were comparable for girls and boys.
Conclusions: Interventions aimed at reducing the adverse effects of ADHD might profitably target prevention or treatment of temporally secondary co-morbid disorders.
Similar articles
-
Lifetime co-morbidity of DSM-IV disorders in the US National Comorbidity Survey Replication Adolescent Supplement (NCS-A).Psychol Med. 2012 Sep;42(9):1997-2010. doi: 10.1017/S0033291712000025. Epub 2012 Jan 25. Psychol Med. 2012. PMID: 22273480 Free PMC article.
-
Severity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement.Arch Gen Psychiatry. 2012 Apr;69(4):381-9. doi: 10.1001/archgenpsychiatry.2011.1603. Arch Gen Psychiatry. 2012. PMID: 22474106 Free PMC article.
-
Prevalence, correlates, and treatment of lifetime suicidal behavior among adolescents: results from the National Comorbidity Survey Replication Adolescent Supplement.JAMA Psychiatry. 2013 Mar;70(3):300-10. doi: 10.1001/2013.jamapsychiatry.55. JAMA Psychiatry. 2013. PMID: 23303463 Free PMC article.
-
Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview.J Clin Psychiatry. 1998;59 Suppl 7:50-8. J Clin Psychiatry. 1998. PMID: 9680053 Review.
-
Completed suicide, ideation and attempt in attention deficit hyperactivity disorder.Acta Psychiatr Scand. 2012 Feb;125(2):93-102. doi: 10.1111/j.1600-0447.2011.01798.x. Epub 2011 Nov 25. Acta Psychiatr Scand. 2012. PMID: 22118301 Review.
Cited by
-
Risk and protective factors for comorbid internalizing and externalizing problems among economically disadvantaged African American youth.Dev Psychopathol. 2017 Aug;29(3):1043-1056. doi: 10.1017/S0954579416001012. Epub 2016 Oct 19. Dev Psychopathol. 2017. PMID: 27758730 Free PMC article.
-
Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity Disorder.JAMA Netw Open. 2019 Jul 3;2(7):e197850. doi: 10.1001/jamanetworkopen.2019.7850. JAMA Netw Open. 2019. PMID: 31348506 Free PMC article.
-
Closed-loop brain training: the science of neurofeedback.Nat Rev Neurosci. 2017 Feb;18(2):86-100. doi: 10.1038/nrn.2016.164. Epub 2016 Dec 22. Nat Rev Neurosci. 2017. PMID: 28003656 Review.
-
Delineating early developmental pathways to ADHD: Setting an international research agenda.JCPP Adv. 2023 Feb 13;3(2):e12144. doi: 10.1002/jcv2.12144. eCollection 2023 Jun. JCPP Adv. 2023. PMID: 37753147 Free PMC article.
-
Measurement invariance of the Child Behavior Checklist (CBCL) across race/ethnicity and sex in the Adolescent Brain and Cognitive Development (ABCD) study.Psychol Assess. 2024 Aug;36(8):441-451. doi: 10.1037/pas0001319. Epub 2024 May 23. Psychol Assess. 2024. PMID: 38780543 Free PMC article.
References
-
- Angold A, Costello EJ, Erkanli A. Comorbidity. Journal of Child Psychology and Psychiatry. 1999;40:57–87. - PubMed
-
- Angold A, Erkanli A, Farmer EM, Fairbank JA, Burns BJ, Keeler G, Costello EJ. Psychiatric disorder, impairment, and service use in rural African American and white youth. Archives of General Psychiatry. 2002;59:893–901. - PubMed
-
- Barkley RA. Distinguishing sluggish cognitive tempo from ADHD in children and adolescents: executive functioning, impairment, and comorbidity. Journal of Clinical Child and Adolescent Psychology. 2013;42:161–173. - PubMed
-
- Bauermeister JJ, Shrout PE, Ramirez R, Bravo M, Alegria M, Martinez-Taboas A, Chavez L, Rubio-Stipec M, Garcia P, Ribera JC, Canino G. ADHD correlates, comorbidity, and impairment in community and treated samples of children and adolescents. Journal of Abnormal Child Psychology. 2007;35:883–898. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
- R01 DA016558/DA/NIDA NIH HHS/United States
- R01 MH066627/MH/NIMH NIH HHS/United States
- U01-MH60220/MH/NIMH NIH HHS/United States
- R01-MH070884/MH/NIMH NIH HHS/United States
- R01 MH069864/MH/NIMH NIH HHS/United States
- R01-MH069864/MH/NIMH NIH HHS/United States
- U01MH060220-09S1/MH/NIMH NIH HHS/United States
- R13-MH066849/MH/NIMH NIH HHS/United States
- R01-MH077883/MH/NIMH NIH HHS/United States
- R01 MH070884/MH/NIMH NIH HHS/United States
- R01 MH077883/MH/NIMH NIH HHS/United States
- R13 MH066849/MH/NIMH NIH HHS/United States
- R03 TW006481/TW/FIC NIH HHS/United States
- R01- DA016558/DA/NIDA NIH HHS/United States
- K05 DA015799/DA/NIDA NIH HHS/United States
- R03-TW006481/TW/FIC NIH HHS/United States
- U01 MH060220/MH/NIMH NIH HHS/United States
- R01-MH66627/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical